Goodwin Advises insitro in Strategic Collaboration With AstraZeneca for AI-enabled Discovery of Novel Therapeutics for MASH and Cardiomyopathies

Professionals

The Life Sciences team advised insitro on its worldwide exclusive research collaboration agreement with AstraZeneca to discover novel targets and therapeutics in metabolic dysfunction-associated steatohepatitis (MASH) and cardiomyopathies. Under the terms of the agreement, insitro will receive $40 million upfront and is eligible for up to approximately $1.46 billion in potential discovery, development, and commercial milestones. In addition, single-digit royalties will be based on potential global commercial sales.

insitro will apply its Virtual Human™ platform to identify causal disease biology in both indications and advance AstraZeneca-nominated targets from discovery through to development candidate. AstraZeneca will lead all clinical development, regulatory work, and commercialization activities.

insitro is the physical AI company unlocking causal human biology to systematically advance high-value therapeutics to treat grievous illness, founded and led by AI pioneer Daphne Koller. insitro has built the world’s largest integrated multi-modal corpus of human and cellular data — the Virtual Human™, a genetically anchored AI engine that reveals how disease begins, progresses, and can be resolved; and the TherML™ platform, which designs medicines against the causal drivers it identifies. Every interrogated disease makes the model smarter, compounding the company’s lead as the corpus grows. The long-term goal is to make health predictable by turning biology into a true AI problem.

The Goodwin team was led by Erini Svokos with invaluable assistance from Shane Albright.

For more information on the deal, please read the press release as well as coverage in Endpoints News and The Wall Street Journal.

Goodwin Advises insitro in Strategic Collaboration With AstraZeneca for AI-enabled Discovery of Novel Therapeutics for MASH and Cardiomyopathies

Related Content

SEC Issues Section 21(a) Report on Investor Coalitions, “Group” Formation, and Schedule 13G Eligibility

Sanofi and Regeneron Expand Immunology Collaboration in Deal Worth Up to $8 Billion

Celltrion Launches Omalizumab Biosimilar in the United States

Sandoz and mABxience Announce Collaboration for Proposed Emicizumab Biosimilar

Stopping Disputes Before They Derail Innovation: The Emerging Role of Life Sciences Dispute Review Boards

Biocon’s Pertuzumab Biosimilar Receives Positive CHMP Opinion Under EMA’s Tailored Clinical Approach

Nektar v. Lilly: Lilly Defeats CRE Claim, but Jury Finds It Owes $90M for Breaching the Implied Covenant of Good Faith and Fair Dealing

Preliminary Injunctive Relief in Trade Secret Cases: When to Move and What to Prove

Goodwin Advises OMass Therapeutics on $310 Million Series C

Goodwin’s UK Platform Highly Ranked in Chambers UK 2027

Goodwin Advises TRex Bio on Intellectual Property Aspects for $117 Million Initial Public Offering

Barry Z. Bazian Named to American Bankruptcy Institute’s 40 Under 40

Goodwin Advises BioGeneration Ventures, Angelini Ventures, and Kurma Partners on $58 Million Series A Financing of RougeTx

Goodwin Advises Repligen Corporation on the Acquisition of BioLife Solutions

Goodwin Advises Alentis on Global Collaboration Agreement With CSL for $355 Million Upfront and Up to $1.2 Billion in Milestone Payments and Worldwide Profit Share

Naomi Birbach and Alicia Palladino Named 2026 Managing IP Rising Stars

Life Sciences